ACT-539313

DRUG2 trials

Sponsors

Idorsia Pharmaceuticals Ltd.

Conditions

Binge-Eating DisorderHealthy

Phase 1

A Study to Investigate the Effect of Single and Repeated Oral Doses of ACT-539313 on What the Body Does to Flurbiprofen, Omeprazole, Midazolam in Healthy Subjects

CompletedNCT05254548

Idorsia Pharmaceuticals Ltd.Healthy

Start: 2022-02-18End: 2022-04-13Updated: 2022-05-04

Phase 2

Multicenter Study to Evaluate the Efficacy and Safety of Oral ACT-539313 in the Treatment of Adults With Moderate to Severe Binge Eating Disorder

CompletedNCT04753164

Idorsia Pharmaceuticals Ltd.Binge-Eating Disorder

Start: 2021-02-16End: 2022-03-25Updated: 2023-03-31

Related Papers

Effect of nivasorexant (<scp>ACT</scp>‐539313), a selective orexin‐1‐receptor antagonist, on multiple cytochrome <scp>P450</scp> probe substrates in vitro and in vivo using a cocktail approach in healthy subjects

Pharmacology Research & Perspectives2023-10-015 citations